Tags: Cancer | non-small cell lung cancer | necitumumab | IMC-11F8 | chemotherapy

New Lung Cancer Drug Works in Trial

Tuesday, 13 Aug 2013 12:06 PM

 


Eli Lilly and Co said its experimental lung cancer drug increased survival of patients in a late-stage trial, and the company plans to file for a U.S. marketing application before the end of 2014.
Lilly shares were up 4 percent in premarket trading.
The drug, necitumumab or IMC-11F8, was given to patients with advanced non-small cell lung cancer in combination with already-approved chemotherapy drug gemcitabine and cisplatin, and was compared with chemotherapy alone.
"If approved, necitumumab could be the first biologic therapy indicated to treat patients with squamous lung cancer," Richard Gaynor, Lilly's vice president for product development and medical affairs, said in a statement.
The company's stock closed at $54.05 on the New York Stock Exchange on Monday.

© 2015 Thomson/Reuters. All rights reserved.

Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

More Measles in January Than Entire Typical Year: CDC

Friday, 30 Jan 2015 08:02 AM

The United States has seen more cases of measles in January than it usually does in an entire year, federal health offic . . .

Some Doctors Won't See Patients With Anti-Vaccine Views

Thursday, 29 Jan 2015 17:15 PM

With California gripped by a measles outbreak, Dr. Charles Goodman posted a clear notice in his waiting room and on Face . . .

Scientists Discover Fast Method to Determine Concussion Severity

Thursday, 29 Jan 2015 17:09 PM

A new eye-tracking method might help determine the severity of concussions, researchers report.

They said the . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved